Opdivo Singled Out in Government Rule Change
The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...
5.9k Views
Mani Inc (7730 JP): Margins Expand in Q1FY26, Dia-Bur Sale Resume in China, FY26 Guidance Reiterated
Mani Inc saw revenue growth and margin improvement in Q1FY26, expects full recovery in sales with dia-bur resumption in China and reiterated FY26...
298 Views
Mani Inc (7730 JP): FY26 Guidance Point Towards a Recovery, Unleashing A Long-Term Play Mode
Mani Inc FY25 revenue up 5% to ¥29.9B, operating margin down to 27.3%. Recalls drag Dental segment. Expect full sales recovery in FY26, revenue to...
665 Views
Mani Inc (7730 JP): Dental Recalls Still a Pain Point, Guidance Revised Downwards
Mani's dental segment reported sales drop of 10% in 9MFY25, with the segment reporting the worst operating margin decline from 19.6% to 10.4%....
582 Views
Kitazato IPO Trading - Demand Was Strong
Kitazato (368A JP) manufactures and sells medical devices and products for fertility treatment. It raised around US$130m in its Japan IPO. In this...
474 Views